treprostinil

Also Known As:

((1R,2R,3AS,9AS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3A,4,9,9A-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; Orenitram; Remodulin; UT-15; UT-15C; trepostinil sodium; treprostinil diethanolamine; treprostinil diolamin; treprostinil diolamine; treprostinil sodium

Networked: 426 relevant articles (62 outcomes, 79 trials/studies)

Relationship Network

Drug Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Unsaturated Fatty Acids: 8236
    - Eicosanoids: 3262
      - Prostaglandins: 17100
        Prostaglandins I: 108
        Epoprostenol: 4670
        treprostinil: 426
Biological Factors: 2472
- Inflammation Mediators: 1113
  - Autacoids: 276
    - Eicosanoids: 3262
      - Prostaglandins: 17100
        Prostaglandins I: 108
        Epoprostenol: 4670
        treprostinil: 426

Experts

1.	Rubin, Lewis J: 16 articles (01/2021 - 03/2002)
2.	White, R James: 15 articles (01/2022 - 02/2010)
3.	Tapson, Victor F: 14 articles (01/2022 - 02/2003)
4.	Gomberg-Maitland, Mardi: 13 articles (01/2021 - 11/2005)
5.	Benza, Raymond L: 12 articles (01/2022 - 12/2005)
6.	Feldman, Jeremy: 12 articles (01/2021 - 09/2013)
7.	Seeger, Werner: 12 articles (03/2017 - 01/2006)
8.	Laliberte, Kevin: 12 articles (02/2017 - 08/2004)
9.	Barst, Robyn J: 11 articles (09/2013 - 03/2002)
10.	Bourge, Robert C: 10 articles (01/2021 - 03/2002)

Related Diseases

1.	Pulmonary Arterial Hypertension 11/01/2023 - "EXPEDITE (NCT03497689), a single-arm, multicenter study, assessed the efficacy of rapid parenteral treprostinil induction to quickly reach higher doses of oral treprostinil for the treatment of pulmonary arterial hypertension. " 04/12/2023 - "Overall, the results indicate that the developed drug in the adhesive patch can effectively deliver treprostinil through the skin and could be a promising treatment option for pulmonary arterial hypertension." 12/01/2012 - "Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although their administration routes have limitations. " 01/01/2008 - "Subcutaneous treprostinil is an effective treatment for pulmonary arterial hypertension (PAH). " 03/01/2006 - "Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial."
2.	Pulmonary Hypertension 01/01/2018 - "In this cohort, treprostinil use was associated with improved severity of pulmonary hypertension assessed by echocardiogram and decreased BNP, with no significant side effects." 07/01/2012 - "First-line treatment of severe pre-capillary pulmonary hypertension with sub-cutaneous treprostinil is safe and efficacious over many years. " 01/01/2019 - "Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?" 09/23/2019 - "Recently, a first randomized trial performed in patients with chronic thromboembolic pulmonary hypertension confirmed the efficacy of subcutaneous treprostinil in this subset of pulmonary hypertension. " 01/01/2008 - "There are uncontrolled data suggesting efficacy of subcutaneous treprostinil in chronic thromboembolic pulmonary hypertension. "
3.	Disease Progression 05/22/2023 - "The INCREASE trial, a phase III multicenter, randomized, placebo-controlled trial demonstrated both improved 6-min walk distance and decreased disease progression with inhaled treprostinil. " 01/01/2022 - "These results support the continuation of inhaled treprostinil despite the occurrence of disease progression in clinical practice." 01/01/2022 - "Conclusions: Patients who received inhaled treprostinil were significantly less likely to experience further disease progression events after an initial event compared with patients receiving placebo. " 01/01/2022 - "Measurements and Main Results: In total, 147 disease progression events occurred in the inhaled treprostinil group (89/163 patients, 55%) compared with 215 events (109/163 patients, 67%) in the placebo group (P = 0.018). " 01/01/2022 - "Objectives: This post hoc analysis evaluated the effect of continued treatment with inhaled treprostinil on the frequency and impact of multiple disease progression events. "
4.	Reperfusion Injury 11/01/2022 - "Treprostinil Supplementation Ameliorates Hepatic Ischemia Reperfusion Injury and Regulates Expression of Hepatic Drug Transporters: An Isolated Perfused Rat Liver (IPRL) Study." 11/01/2021 - "Treprostinil alleviates hepatic mitochondrial injury during rat renal ischemia-reperfusion injury." 09/01/2021 - "Treprostinil reduces mitochondrial injury during rat renal ischemia-reperfusion injury." 09/27/2023 - "Treprostinil exhibits vasodilatory properties and antiplatelet activity and regulates proinflammatory cytokines; therefore, it can potentially minimize ischemia-reperfusion injury. " 01/01/2021 - "An evaluation of the safety and preliminary efficacy of peri- and post-operative treprostinil in preventing ischemia and reperfusion injury in adult orthotopic liver transplant recipients."
5.	Lung Diseases (Lung Disease) 06/01/2023 - "Patients who received inhaled treprostinil versus placebo in the RCT had a 31% lower relative risk of exacerbation of underlying lung disease in the OLE (hazard ratio 0.69 (95% CI 0.49-0.97); p=0.03). " 01/01/2018 - "In the present retrospective study, data from 22 patients with PH associated with lung disease treated with inhaled treprostinil (iTre) and followed up clinically for at least 3 months are presented. " 07/01/2014 - "In our experience with 5 former extremely preterm infants who had PAH associated with chronic lung disease, subcutaneous treprostinil was safe, efficacious, and well tolerated. " 07/01/2022 - "Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing." 01/01/2022 - "There was a lower incidence of each disease progression component in the inhaled treprostinil group: 6-minute-walk distance decline (45 vs. 64 events), lung disease exacerbation (48 vs. 72 events), FVC decline (19 vs. 33), cardiopulmonary hospitalization (23 vs. 33 events), and death (10 vs. 12). "

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	Sildenafil Citrate (Viagra)
3.	Iloprost (Ventavis)
4.	treprostinil
5.	selexipag
6.	Vasodilator Agents (Vasodilators)
7.	Bosentan (Tracleer)
8.	Prostaglandins
9.	beraprost
10.	Prostaglandins I

Related Therapies and Procedures

1.	Therapeutics
2.	Liver Transplantation
3.	Lung Transplantation
4.	Conservative Treatment
5.	Subcutaneous Infusions